Literature DB >> 19885608

Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma.

Katrin Steinmann1, Annett Sandner, Undraga Schagdarsurengin, Reinhard H Dammann.   

Abstract

Squamous cell carcinomas of head and neck (HNSCC) are a result of multiple genetic and epigenetic alterations. Epigenetic inactivation of tumor suppressor genes is an important event in head and neck carcinogenesis. Here we analyzed the promoter methylation of 15 genes (RASSF1A, p16, MGMT, DAPK, RARbeta, MLH1, CDH1, GSTP1, RASSF2, RASSF4, RASSF5, MST1, MST2, LATS1, LATS2) in 54 HNSCC and in matching 23 normal tissues. Methylation of these tumor-related genes (TRG) was significantly more frequent in HNSCC (42%) compared to normal samples (23%; p<0.05). Particularly, methylation of p16 (60%), MGMT (53%), DAPK (67%), RARbeta (75%), MLH1 (69%), CDH1 (43%), RASSF5 and MST1 (96%) was often found in HNSCC. Methylation of RASSF1A (18%), GSTP1 (4%), RASSF4 (13%), MST2 (4%), LATS1 (24%) and LATS2 (8%) was less frequently detected. A trend of increased TRG methylation in more advanced tumor stages and less differentiated HNSCC was observed. Methylation of p16 was significantly higher in poorly differentiated HNSCC (p=0.037) and RASSF5 methylation occurred preferentially in advanced tumor stages (p<0.05). Methylation of RASSF4 was higher in patients with recurrent HNSCC (23%) than patients without relapse (0%; p=0.033). Methylation of TRG in head and neck cancer cell lines was observed at similar frequency as in primary HNSCC. In summary, frequent hyper-methylation of tumor-related genes in HNSCC was detected and this epigenetic silencing event may have an essential role in head and neck carcinogenesis.

Entities:  

Mesh:

Year:  2009        PMID: 19885608     DOI: 10.3892/or_00000596

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  70 in total

Review 1.  Epigenetic changes of DNA repair genes in cancer.

Authors:  Christoph Lahtz; Gerd P Pfeifer
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

2.  Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth.

Authors:  L Li; R Fang; B Liu; H Shi; Y Wang; W Zhang; X Zhang; L Ye
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

3.  Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.

Authors:  D Aydin; A Bilici; S Kayahan; D Yavuzer; M Basar; M Aliustaoglu
Journal:  Clin Transl Oncol       Date:  2015-10-12       Impact factor: 3.405

4.  A kinase shRNA screen links LATS2 and the pRB tumor suppressor.

Authors:  Katrin Tschöp; Andrew R Conery; Larisa Litovchick; James A Decaprio; Jeffrey Settleman; Ed Harlow; Nicholas Dyson
Journal:  Genes Dev       Date:  2011-04-15       Impact factor: 11.361

5.  RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma.

Authors:  Wei Guo; Cong Wang; Yanli Guo; Supeng Shen; Xin Guo; Gang Kuang; Zhiming Dong
Journal:  Clin Exp Metastasis       Date:  2015-01-13       Impact factor: 5.150

6.  DNA methylation biomarkers for head and neck squamous cell carcinoma.

Authors:  Chongchang Zhou; Meng Ye; Shumin Ni; Qun Li; Dong Ye; Jinyun Li; Zhisen Shen; Hongxia Deng
Journal:  Epigenetics       Date:  2018-08-10       Impact factor: 4.528

7.  Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.

Authors:  Showkat A Malik; Mosin S Khan; Majeed Dar; Mahboob Ul Hussain; Mohammad A Shah; Sheikh M Shafi; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2017-04-22       Impact factor: 3.201

8.  MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.

Authors:  S Trabelsi; N Mama; M Ladib; N Karmeni; M Haddaji Mastouri; M Chourabi; M Mokni; K Tlili; H Krifa; M T Yacoubi; A Saad; D H'mida Ben Brahim
Journal:  Clin Transl Oncol       Date:  2015-08-20       Impact factor: 3.405

9.  Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences.

Authors:  Undraga Schagdarsurengin; Antje M Richter; Juliane Hornung; Cornelia Lange; Katrin Steinmann; Reinhard H Dammann
Journal:  Mol Cancer       Date:  2010-09-29       Impact factor: 27.401

10.  Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma.

Authors:  Tao Wang; Hongli Liu; Yeshan Chen; Wei Liu; Jing Yu; Gang Wu
Journal:  J Exp Clin Cancer Res       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.